List of accepted posters


Nr Title / Authors

2

Comprehensive bioinformatic analysis of HIV-1 protease specificity
Liwen You
Halmstad University, Sweden

3

The role of recombination in HIV evolution
Andreas Meyerhans et al
Department of Virology, University of the Saarland

4

Molecular epidemiology of hepatitis C virus in the Valencia region (Spain)
Fernando González-Candelas et al
Evolutionary Genetics Unit, “Cavanilles” Institute for Biodiversity and Evolutionary Biology, University of Valencia

5

Genetic variability and relatedness of hepatitis C virus strains and their effects on liver fibrosis progression
Xavier López-Labrador and Fernando Gonzalez-Candelas
“Cavanilles” Institute for Biodiversity and Evolutionary Biology, University of Valencia, and Public Health Department, Generalitat Valenciana.

6

Virus dynamics: Basic and detailed models of influenza A virus replication in mammalian cells
Udo Reichl
Max-Planck-Institute for Dynamics of Complex Technical Systems, Magdeburg, Germany

7

Modelling in-vivo HIV evolutionary mutational pathways under AZT-3TC regimen through Markov Chains
Mattia Prosperi
Faculty of Computer Engineering - University of Roma TRE

8

The European hepatitis C virus data base
Christophe Combet
Institut de Biologie et Chimie des Protéines, Lyon France

9

Selection of potential Cytotoxic T lymphocyte epitopes conserved among related Orthopoxviruses using a Bioinformatic Appoach
Sheila Tuyet Tang et al
Center for Biological Sequence Analysis, Technical University of Denmark

10

Phylogeny of HIV-1 subtype B in Denmark year 2001-2003
Audelin, A. M
Department of Life Sciences and Chemistry, Roskilde University Centre, Denmark.

11

Fold predictions of HIV-1 p1 RNA from therapy-naive and -experienced patients suggest contribution to drug resistance
Jens Verheyen
Institute for Virology, University of Cologne

12

Amino acid variations in HCV p7 and sensitivity to antiviral combination therapy with amantadine in chronic hepatitis C
Christoph Welsch
Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany

13

Detection and analysis of drug resistance mutations: Bioinformatics challenges and solutions.
Mahanandeeshwar Gattu
Research & Development, GlaxoSmithkline, USA & UK

14

Expression of HCV genes by alphavirus replicon vectors – implications for HCV vaccine design
Ekaterina Alekseeva et al
Biomedical Research and Study Centre, University of Latvia

15

Structure based analyses of HIV PI-resistance
Daniel Hoffmann and Oli Grober
Bingen University of Applied Sciences, Bioinformatics Project Group

16

Modelling molecular evolution of influenza
Richard A. Goldstein
National Institute for Medical Research

17

viRgil: An integrated interdisciplinary European Network of Excellence
Ralf Bartenschlager
Department Molecular Virology, University Heidelberg, Germany

18

Characterization on the dynamics of disappearance of protease resistance mutations during treatment interruption
MM Santoro at al
University of Rome Tor Vergata, Rome

19

A cross-talk between cellular and viral proteins: functional inference by a comparative proteome approach
Iris Bahir et al
Hebrew University

20

Treatment history improves the accuracy of neural networks predicting virologic response to HIV therapy
Dechao Wang
HIV Resistance Response Database Initiative, London, UK

21

HLA profiles predict known and novel HIV-1 escape mutations at a population level
K. Roomp et al
MPII, Saarbruecken, Germany

22

Immunological and virological parameters improve genotypic prediction of HIV-1 coreceptor usage
T. Sing
Max Planck Institute for Informatics, Saarbrücken, Germany

23

Geno2pheno and the Arevir database: tools for determination of clinically relevant cut-offs and prediction of viral load change from HIV-1 genotype.
Martin Däumer et al
Institute of Virology, University of Cologne

24

Probabilistic modeling of genetic barriers enables reliable prediction of HAART outcome at below 15% error rate
Martin Däumer
Institute of Virology, University of Cologne, Germany

25

HIV-salvage therapy guided by genotypic resistance testing and the geno2pheno® interpretation system
Mark Oette et al
University of Cologne, Germany

26

Efficacy of first-line antiretroviral HIV-therapy guided by genotypic resistance testing and the geno2pheno® interpretation system
Mark Oette et al
University of Cologne, Germany

27

Building and analysing an integrative model of HIV-1 RNA alternative splicing
A. Bockmayr et al
DFG Research Center Matheon & FU Berlin, Germany

28

Susceptibility to saquinavir and atazanavir in highly protease inhibitor (PI) resistant HIV-1 is caused by lopinavir-induced drug resistance mutation L76V
Hauke Walter et al
Institute for Virology, Cologne, Germany

29

Towards molecular characterization of HIV-vif interaction with human Apobec-3G
C. Cramer von Laue et al
centre of advanced european studies and research, Bonn, Germany

30

Developing a web-accessible, quality-based, molecular, clinical and epidemiological Database for hepatitis B infection
Jonathan Green et al
Centre for Infections, Health Protection Agency, London, UK

31

Relation of 2D and 3D descriptors of HIV protease inhibitors to drug resistance
F.Cordes et al
Zuse Institut Berlin (ZIB)